Related Experiment Video
Updated: Jul 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination
1Baylor College of Medicine, Section of Lipid and Atherosclerosis, Houston, TX 77030, USA. rneal@bcm.tmc.edu
Insights
New guidelines recommend lower LDL-C goals for high-risk patients. Ezetimibe/simvastatin offers an effective option for achieving these targets in cardiovascular disease management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease (CVD) is the leading cause of death in the USA.
- Declining coronary heart disease (CHD) death rates may stem from aggressive management of risk factors like hypertension, diabetes, and dyslipidemia.
Purpose of the Study:
- To review updated National Cholesterol Education Program (NCEP) guidelines for low-density lipoprotein cholesterol (LDL-C) goals.
- To discuss the efficacy and safety of ezetimibe/simvastatin as a lipid-lowering therapy.
Main Methods:
- Review of updated NCEP guidelines.
- Analysis of clinical data on ezetimibe/simvastatin efficacy and safety for LDL-C reduction.
Main Results:
- Updated NCEP guidelines necessitate more potent lipid-lowering therapies.
- Ezetimibe/simvastatin demonstrates efficacy in lowering LDL-C to meet new targets.
Conclusions:
- Clinicians require effective therapies to meet new, lower LDL-C goals.
- Ezetimibe/simvastatin is a viable option for managing high LDL-C in high-risk patients.
Abstract:
Cardiovascular (CV) disease remains the number 1 cause of death in the USA. Nonetheless, there has been a decline in the age-adjusted death rate for coronary heart disease (CHD) which may be due to more aggressive treatment guidelines for treating CV risk factors, such as hypertension, diabetes, and dyslipidemia. The recent update to the National Cholesterol Education Program (NCEP) guidelines have recommended lower low-density lipoprotein cholesterol (LDL-C) goals in high-risk patients. Based on the new targets for LDL-C, clinicians will need more efficacious lipid-lowering therapies. One of these newer therapies is the combination of ezetimibe and simvastatin. This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Lipids: Dietary Sources and Requirements
Coronary Artery Disease V: Interprofessional Care
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets